Bruno SARMENTO profile

Bruno Sarmento is Principal Investigator, Group Leader and member of the Board of Directors at Institute for Research and Innovation in Health (i3S), University of Porto (UP), and Invited Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal. He also co-founded Inovapotek in 2008, and is member of its advisory board. He was Visiting Professor at UniOeste (BR) between 2015-2017 and at Shanghai Jiao Tong University School of Medicine (CH) between 2022-2024. He supervised/co-supervised 21 Post-Docs, 61 PhD students, 45 MSc students and 17 researcher assistants. He attracted direct competitive funding worth more than 25 M€, at national and international levels. His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He edited 6 books, participated in more than 70 invited/selected talks in national and international meetings and was awarded several distinctions. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of several international journals, including the Journal of Controlled Release, Drug Delivery and Translational Research, Expert Opinion on Drug Delivery and Smart Materials in Medicine. He is referee for top-ranked journals in his area of expertise, and for international funding agencies. Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS), was Director-at-Large for the last three years and recently elected Secretary of the CRS. He is also member of CRS College of Fellows.

Bruno Sarmento’s interests are focused on drug delivery systems, with special attention on nanotechnology, and their interdisciplinary application to the pharmaceutical and biomedical fields. He is interested in engineering targeted nanomedicines by identifying novel biological targets, proposing new functional ligands and producing tailored nanoplatforms for the delivery of therapeutic molecules for managing diabetes, cancer, infection and metabolic diseases. He pioneered nanofabrication approaches using different macro and microfluidics methodologies that allow for the encapsulation of small molecules and biopharmaceuticals for distinct purposes and their functionalization with active ligand moieties to target biological receptors. His research contributes with fundamental insights on nanocarriers used for drug delivery applications in order to understand their mechanism of transport at the tissue and cellular levels and on the advantages of nanosystems used for prevention, diagnostics and therapy. In particular, he is committed to unravel the real value of “nano” for mucosal drug delivery; develop mucodiffusive, molecular bioengineered nanoparticles for the oral delivery of antidiabetic peptides; establish advanced multistage functionalized nanoparticles for diagnostic and treatment of colorectal cancer and glioblastoma; and develop nanotechnology-based platforms for prevent and treat infections. He has also specialized in tissue bioengineering 3D multicompartmental models to validate functionalized nanomedicines and in vitro/in vivo correlation.

Personal web site: https://www.i3s.up.pt/research-group?x=109 Google Scholar: http://scholar.google.pt/citations?hl=pt-PT&user=ykwPJ1QAAAAJ Scopus: https://www.scopus.com/authid/detail.url?authorId=14014524100 Orcid: https://orcid.org/0000-0001-5763-7553